Upon successful completion of these requirements,
you will receive a printable credit statement.
If you have any
questions about this process, please email
the Center for Continuing and Outreach
Education at email@example.com or call CCOE Enrollment Services at (800) 227-4852.
Sponsored by François-Xavier Bagnoud Center, School of Nursing, University of Medicine and Dentistry of New Jersey and UMDNJ-Center for Continuing and Outreach Education.
This activity is supported by an educational grant from the New Jersey Department of Health (NJDOH)—Division of HIV, STD and TB Services, through an MOA titled “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS.”
Statement of Need
Despite the fact that tuberculosis (TB) has become an increasingly uncommon disease in the United States, it still remains a public health problem of enormous importance, and this importance is amplified by the synergistic effects of latent TB infection (LTBI) in those who are HIV-infected (i.e., TB-HIV co-infection). TB contributes substantially to morbidity and mortality of people living with HIV who are foreign-born, who also comprise an increasing proportion of those newly diagnosed with HIV infection.
There have been important recent advances in tools to diagnose LTBI and active TB including interferon-gamma release assays (IGRAs). There are also new short course regimens available for the treatment of LTBI. However there have also been unforeseen challenges to treatment of LTBI and TB disease due to shortages of important anti-tuberculosis agents, including the current nationwide shortage of isoniazid (INH) tablets.
The greatest new challenge to recent progress in global control of TB has been the continuing emergence of multi-drug resistant (MDR) and extensively drug resistant (XDR) strains of TB. Treatment of drug resistant TB involves use of more prolonged, more toxic and less effective therapies and significantly increases the cost of TB care. The emergence of drug-resistant TB has spurred development and deployment of new, rapid tools for simultaneous identification of both TB disease and drug resistance, and has also sparked the development of new drugs for treatment of MDR strains.
This activity is designed for physicians, nurses, social workers, health educators, and other health care professionals in New Jersey who are involved in the care of people with HIV.
Method of Participation
Participants should read the learning objectives, review the activity in its entirety, and then complete the self-assessment test, which consists of a series of multiple-choice questions. Upon completing this activity as designed, achieving a passing score of 70% or more on the self-assessment test and submitting a course evaluation, participants will receive a printable credit statement.
Estimated time to complete this activity as designed is 1.00 hour for nurses, and 0.75 hour for physicians.
Upon completion of this activity, participants should be able to:
- Describe the tools used to diagnose TB disease and LTBI.
- Summarize the treatment options for LTBI.
- Summarize the new tools for diagnosing and new drugs for treating MDR and XDR TB.
Activity Director(s)/CME Academic Advisor(s)
Patricia Kloser, MD, MPH,
Professor of Medicine, UMDNJ-New Jersey Medical School and UMDNJ-School of Public Health
Margaret Evans, MSN, RN, Lead Nurse Planner, Nurse Manager for Education and Performance Improvement at Robert Wood Johnson Medical Group.
Virginia Allread, MPH, AIDSLine Editor and Global Program Director, FXB Center, UMDNJ
Linda Berezny, RN BA Supervising Program Development
Specialist Prevention and Education, NJDOH,
Division of HIV, STD and TB Services
Alicia Gambino, MA, CHES, Director of Public Education, New Jersey Poison Information & Education System
Sindy Paul, MD, MPH, FACPM, Medical Director, NJDOH, Division of HIV, STD and TB Services
Joanne Phillips, RN, MS, Education,
Specialist, FXB Center, UMDNJ
Renee Powell, BS, RN, Clinical Coordinator Quality Management, FXB Center, UMDNJ
Sarah Quinless, BA, Program
Coordinator, FXB Center, UMDNJ
Michelle Thompson, Program Manager, FXB Center, UMDNJ
Elizabeth Ward, MSJ, Executive Director, CCOE, UMDNJ
Henry Shalom Fraimow, MD, Associate Professor of Medicine, UMDNJ-Robert Wood Johnson Medical School and Attending Physician, Cooper University Hospital
UMDNJ–Center for Continuing and Outreach Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
UMDNJ–Center for Continuing and Outreach Education designates this enduring material for a maximum of 0.75 AMA PRA Category Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
UMDNJ-Center for Continuing and Outreach Education is an approved provider of continuing nursing education by New Jersey State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider Number TP173-12/12-15. Provider Approval is valid through December 31, 2015.
This activity is awarded 1.00 contact hour (60 minute CH).
Nurses should only claim those contact hours actually spent participating in the activity.
Approved provider status refers only to continuing education activities and does not imply ANCC COA or NJSNA endorsement of any commercial products.
UMDNJ-CCOE certifies that this continuing education offering meets the criteria for up to 0.1 Continuing Education Units (CEUs), provided the activity is completed as designed. One CEU equals 10 contact hours of participation in an organized continuing education experience under responsible sponsorship, capable direction and qualified instruction. Participants should only claim those contact hours actually spent participating in the activity.
In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, UMDNJ-CCOE has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content and balance of presentation by Joanne Phillips, RN, MS.
This activity was pilot-tested for time required for participation by Bonnie R. Abedini, MSN, RN; David John Cennimo, MD; Jojy Cheriyan, MD, MPH, MPhil; Anna M. Haywood, RN, MSN; Mary C. Krug, RN, MSN, APN; Kinshasa Morton, MD; Shobha Swaminathan, MD; and Kara Winslow, BSN, RN.
In accordance with the disclosure policies of UMDNJ and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/ device not yet approved.
There were no relevant financial relationships to disclose reported by the activity directors, the author, planning committee members, the peer reviewer or field testers. However, the author’s spouse, Jacqueline French, MD, received grant funding from the Milken Foundation, the Epilepsy Therapy Project, and NINDS. She serves as the president of the Epilepsy Study Consortium, a nonprofit organization. NYU receives a fixed amount from the Epilepsy Study Consortium towards Dr. French’s salary for consulting and clinical trial-related activities. Dr. French receives no personal income for these activities. Within the past year the Epilepsy Study Consortium received payments from the following: Biotie, Cyberonics, Eisai Medical Research, Entra Pharmaceuticals, GlaxoSmithKline, Icagen, Inc., Johnson & Johnson, Mapp Pharmaceuticals, Marinus, Neurotherapeutics, Neuropace, NeuroVista Corporation, Ono Pharma USA, Inc., Lundbeck, Pfizer, Sepracor, Sunovion, SK Life Science, Supernus Pharmaceuticals, UCB Inc/Schwarz Pharma, Upsher Smith, Valeant, Vertex.
Off-Label Usage Disclosure
This activity provides an overview of Xpert MTB/RIF Assay, which — although endorsed by WHO — is not yet FDA approved. This activity also includes mention of delamanid, a drug for the treatment of MDR-TB that is currently in phase 3 trials. Delamanid is not yet FDA approved.
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of NJDOH – Division of HIV, STD and TB Services, any manufacturer of pharmaceuticals or devices, or UMDNJ. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.
Copyright © 2013 UMDNJ
All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from UMDNJ.
Please direct CE related or technical questions to UMDNJ at 973-972-4267 or email firstname.lastname@example.org.